Related Experiment Video
Updated: May 7, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage occlusion: opportunities and challenges
David R Holmes1, Dhanunjaya R Lakkireddy2, Richard P Whitlock3
1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Insights
Left atrial appendage occlusion offers a stroke prevention alternative for patients with atrial fibrillation, potentially avoiding anticoagulation. Ongoing research supports its role in carefully selected individuals.
Area of Science:
- Cardiology
- Medical Devices
- Stroke Prevention
Background:
- Atrial fibrillation incidence is rising, increasing stroke risk.
- Anticoagulation is standard for stroke prevention but has limitations.
- Left atrial appendage thrombus is a common cause of stroke in atrial fibrillation.
Purpose of the Study:
- To evaluate left atrial appendage occlusion as an alternative to anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
- To address challenges in regulatory approval for left atrial appendage occlusion devices.
- To assess the safety and efficacy of mechanical left atrial appendage exclusion.
Main Methods:
- Review of data from randomized trials and registries.
- Analysis of catheter-based and surgical left atrial appendage occlusion techniques.
- Evaluation of trial design, risk-benefit ratios, patient selection, and endpoints.
Main Results:
- Accumulating data support left atrial appendage exclusion as a viable stroke prevention strategy.
- Longer-term follow-up data are crucial for device approval and clinical adoption.
- Carefully selected patients may benefit from this alternative to anticoagulation.
Conclusions:
- Left atrial appendage occlusion is a promising alternative to anticoagulation for stroke prevention in select atrial fibrillation patients.
- Continued research and optimized trial designs are needed to overcome regulatory hurdles.
- Mechanical exclusion of the left atrial appendage may reduce stroke risk without systemic anticoagulation.
Abstract:
Stroke prevention in patients with atrial fibrillation is a growing clinical dilemma as the incidence of the arrhythmia increases and risk profiles worsen. Strategies in patients with nonvalvular atrial fibrillation have included anticoagulation with a variety of drugs. Knowledge that stroke in this setting typically results from thrombus in the left atrial appendage has led to the development of mechanical approaches, both catheter-based and surgical, to occlude that structure. Such a device, if it were safe and effective, might avoid the need for anticoagulation and prevent stroke in the large number of patients who are currently not treated with anticoagulants. Regulatory approval has been difficult due to trial design challenges, balance of the risk-benefit ratio, specific patient populations studied, selection of treatment in the control group, and specific endpoints and statistical analyses selected. Accumulating data from randomized trials and registries with longer-term follow-up continues to support a role for left atrial appendage exclusion from the central circulation as an alternative to anticoagulation in carefully-selected patient populations.
